Skip to main content

Table 3 Characteristics of patients in the KyberSept trial

From: Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

  Overall population* All 90-day survivors 90-day in-hospital
Parameter Placebo (n = 1157) AT III (n = 1157) Placebo (n = 437) AT III (n = 460) Placebo (n = 55) AT III (n = 63)
Age (years; mean ± SD [range]) 58 ± 17 (18–96) 57 ± 17 (18–93) 53 ± 17 (18–96) 53 ± 17 (18–88) 57 ± 15 (22–81) 56 ± 14 (21–79)
Sex (%)       
   Male 61 62 62 64 67 65
   Female 39 38 38 36 33 35
Country (%)       
   USA 15 15 14 15 6 6
   Czech Republic 11 11 12 11 18 10
   South Africa 11 11 9 8 2 5
   UK 8 8 9 9 13 13
   Denmark 7 7 6 7 6 11
   Germany 6 6 6 5 4 8
   Other (13 countries) 40 40 43 46 53 48
SAPS II risk group (%)       
   Moderate risk (<30%) 27 29 43 40 24 24
   High risk (30–60%) 45 42 40 43 36 41
   Very high risk (>60%) 28 29 17 18 40 35
Admitting diagnosis (%)       
   Respiratory system 34 35 33 34 33 24
   Digestive system 28 27 29 27 38 40
   Genitourinary system 8 6 11 8 4 2
   Injury 6 7 5 7 0 10
   Other 24 24 22 25 26 25
Concomitant heparin (%)       
   No 30 30 29 32 13 30
   Yes 70 70 71 68 87 70
  1. *All 2314 patients evaluable for efficacy in KyberSept study. According to the International Classification of Diseases (9th edition). Percentages may not add to 100 because of rounding. AT, antithrombin; SAPS, Simplified Acute Physiology Score.